GlassScriptPhysician profile
Beau M Hawkins
NPI 1073654893
$11,990.93
in general payments reported to CMS, 2019-2025
26 companies · $593 in 2025
The $593 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $96.74 · 2020: $186 · 2021: $1,223 · 2022: $6,698 · 2023: $2,842 · 2024: $353 · 2025: $593.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $2,400 · Food and Beverage: $1,388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $2,400.00 |
| Food and Beverage | $1,388.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $9,822.64 | 2021-2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Medtronic, INC. | $439.63 | 2021-2025 | Symplicity G3 |
| Novartis Pharmaceuticals Corporation | $205.85 | 2023-2025 | |
| Datascope Corp. | $185.51 | 2020 | |
| Abiomed | $183.76 | 2022 | |
| Cook Medical LLC | $171.90 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $132.99 | 2023-2025 | Lifevest |
| Amgen INC. | $124.73 | 2023-2025 | Repatha, Repatha |
| Neuros Medical, INC. | $119.95 | 2025 | Altius |
| Surmodics, INC. | $99.39 | 2023-2024 | Sublime 014 Rx Pta Balloon Dilatation Catheter, Pounce Venous Thrombectomy System, Sublime Radial Access 018 Rx Pta Dilatation Catheter |
| Astrazeneca Pharmaceuticals LP | $79.71 | 2023-2024 | Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.48 | 2023-2024 | Jardiance |
| Pfizer INC. | $58.69 | 2023-2024 | |
| Philips North America LLC | $56.02 | 2025 | Extended Holter |
| Atricure, INC. | $49.13 | 2023-2024 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $34.19 | 2023-2024 | Eliquis |
| Edwards Lifesciences Corporation | $27.52 | 2021 | |
| Cardiovascular Systems INC. | $24.03 | 2019-2021 | |
| Lexicon Pharmaceuticals, INC. | $22.78 | 2024 | |
| Terumo Medical Corporation | $18.62 | 2021 | |
| Asahi Intecc USA, INC. | $16.05 | 2024 | Peripheral Vascular |
| Janssen Pharmaceuticals, INC | $15.22 | 2022 | |
| Alnylam Pharmaceuticals INC. | $14.14 | 2023 | Onpattro |
| Penumbra, INC. | $13.00 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Beau Hawkins listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.